AbbVie & Amgen: Safe Havens in Tech Downturn
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Tech stocks plummeting? Shift focus to healthcare giants like AbbVie and Amgen. AbbVies stable drug lineup in immunology, oncology, and neuroscience, including Skyrizi, Rinvoq, and Botox, ensures steady sales. Management raised guidance, aiming for thirty-one billion in combined sales by 2026. AbbVies Dividend King status offers stability and reduced volatility. Amgen, despite losing patent protection on Prolia, is bouncing back with Tezspire for asthma and Repatha for cholesterol. Their pipeline, including MariTide for weight loss, promises long-term upside. Both offer reliable dividends and a safer investment option amid market volatility.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/9ddf797083f484e8